Working… Menu
Trial record 1 of 3 for:    ALTA 1L
Previous Study | Return to List | Next Study

ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02737501
Recruitment Status : Completed
First Posted : April 14, 2016
Last Update Posted : December 23, 2020
Information provided by (Responsible Party):
Takeda ( Ariad Pharmaceuticals )